Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Terminated × Melanoma × Tomography, Emission-Computed × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Interventions

pembrolizumab 45 Ipilimumab 39 Cyclophosphamide 38 Nivolumab 33 aldesleukin 26 fludarabine 19 Vemurafenib 19 Interleukin-2 19 dabrafenib 15 Temozolomide 15 fludarabine phosphate 13 trametinib 12 Radiosurgery 9 Dacarbazine 9 spartalizumab 8 cobimetinib 8 binimetinib 8 Radiotherapy 8 poly ICLC 6 encorafenib 6 Introns 6 CTLA-4 Antigen 6 Biopsy 6 montanide ISA 51 5 atezolizumab 4 Interferon alpha-2 4 Immunohistochemistry 4 Celecoxib 4 Bevacizumab 4 tovorafenib 3

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT02236546 2017-04-13

FDG-PET in Advanced Melanoma

Vanderbilt-Ingram Cancer Center

Phase NA Terminated

3 enrolled 4 charts

Melanoma

Data powered by HemOnc (CC BY 4.0) Colophon ⚡